公开(公告)号：US20180273602A1

公开(公告)日：2018-09-27

申请号：US15928785

申请日：2018-03-22

Applicant: Immatics Biotechnologies GmbH

Inventor： Leonie ALTEN ,  Dominik MAURER ,  Sebastian BUNK ,  Claudia WAGNER

IPC: C07K14/725

CPC classification number: C07K14/7051 ,  A61K38/00 ,  C07K14/4748 ,  C07K16/3053 ,  C07K2317/34 ,  C07K2317/73 ,  C07K2317/92

Abstract: The present invention pertains to antigen recognizing constructs against tumor associated antigens (TAA), in particular against Preferentially Expressed Antigen of Melanoma (PRAME). The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen of the invention. The TCR of the invention, and TAA binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of TAA expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.

公开(公告)号：US20180161396A1

公开(公告)日：2018-06-14

申请号：US15834633

申请日：2017-12-07

Applicant: immatics biotechnologies GmbH

Inventor： Leonie ALTEN ,  Sebastian BUNK ,  Dominik MAURER ,  Claudia WAGNER

IPC: A61K38/17 ,  A61K35/17 ,  C07K14/725 ,  C12N15/85 ,  A61P35/00

Abstract: The present invention pertains to antigen recognizing constructs against tumor associated antigens (MAGEA1). The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen of the invention. The TCR of the invention, and TAA binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of TAA expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.

公开(公告)号：US20250093354A1

公开(公告)日：2025-03-20

申请号：US18919930

申请日：2024-10-18

Applicant: Immatics Biotechnologies GmbH

Inventor： Andreas MORITZ ,  Dominik MAURER ,  Sebastian BUNK ,  Claudia WAGNER

IPC: G01N33/569 ,  A61K38/17 ,  A61K39/00 ,  A61K39/395 ,  C07K14/74

Abstract: The present invention relates to a method for high throughput screening for a TCR-binding peptide ligand/MHC molecule complex, comprising a stabilized peptide-MHC molecule and respective uses of said method. The present invention further relates to polypeptides comprising or consisting of stabilized MHC molecules or peptide binding fragments thereof, pharmaceutical compositions comprising said polypeptides, vaccines comprising said pharmaceutical composition and uses of said vaccine for the manufacturing of a medicament and/or in the prevention of cancer The present invention further relates to nucleic acids encoding said polypeptides and vectors comprising said nucleic acids.

公开(公告)号：US20240285779A1

公开(公告)日：2024-08-29

申请号：US18642871

申请日：2024-04-23

Applicant: Immatics Biotechnologies GmbH

Inventor： Leonie ALTEN ,  Sebastian BUNK ,  Dominik MAURER ,  Claudia WAGNER

IPC: A61K47/55 ,  A61K35/17 ,  A61K38/00 ,  A61K38/17 ,  A61K39/00 ,  A61K47/64 ,  A61P35/00 ,  C07K14/47 ,  C07K14/705 ,  C07K14/725 ,  C07K14/73 ,  C12N5/00 ,  C12N15/85

CPC classification number: A61K47/55 ,  A61K35/17 ,  A61K38/1774 ,  A61K39/0011 ,  A61K39/001186 ,  A61K47/64 ,  A61P35/00 ,  C07K14/4748 ,  C07K14/705 ,  C07K14/7051 ,  C12N5/00 ,  C12N15/85 ,  A61K38/00 ,  A61K2039/572 ,  C07K14/70514 ,  C07K14/70517 ,  C07K2317/21 ,  C07K2317/24

Abstract: The present invention pertains to antigen recognizing constructs against tumor associated antigens (MAGEA1). The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen of the invention. The TCR of the invention, and TAA binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of TAA expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.

公开(公告)号：US20230132241A1

公开(公告)日：2023-04-27

申请号：US17793237

申请日：2020-01-15

Applicant: Immatics Biotechnologies GmbH

Inventor： Sebastian BUNK ,  Martin HOFMANN ,  Meike HUTT ,  Dominik MAURER ,  Gabriele PSZOLLA ,  Frank SCHWOEBEL ,  Felix UNVERDORBEN ,  Claudia WAGNER ,  Sara YOUSEF

IPC: C07K16/30 ,  C12N15/63 ,  A61P35/00

Abstract: The present invention concerns antigen binding proteins directed against PRAME protein-derived antigens. The invention in particular provides antigen binding proteins which are selective and specific for the tumor expressed antigen PRAME, wherein the tumor antigen comprises or consists of SEQ ID NO: 8 and is in a complex with a major histocompatibility complex (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said PRAME peptide. The antigen binding proteins of the invention are for use in the diagnosis, treatment and prevention of PRAME expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising said nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.

公开(公告)号：US20230094790A1

公开(公告)日：2023-03-30

申请号：US17937285

申请日：2022-09-30

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： Toni WEINSCHENK ,  Jens FRITSCHE ,  Harpreet SINGH ,  Andrea MAHR ,  Martina OTT ,  Claudia WAGNER ,  Oliver SCHOOR

IPC: A61K39/00 ,  C07K14/47 ,  C07K14/74 ,  C07K16/18 ,  C12N15/115

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20230051035A1

公开(公告)日：2023-02-16

申请号：US17937268

申请日：2022-09-30

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： Toni WEINSCHENK ,  Jens FRITSCHE ,  Harpreet SINGH ,  Andrea MAHR ,  Martina OTT ,  Claudia WAGNER ,  Oliver SCHOOR

IPC: A61K39/00 ,  C07K14/47 ,  C07K14/74 ,  C07K16/18 ,  C12N15/115

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20220372165A1

公开(公告)日：2022-11-24

申请号：US17736882

申请日：2022-05-04

Applicant: Immatics Biotechnologies GmbH

Inventor： Gabriele PSZOLLA ,  Martin HOFMANN ,  Meike HUTT ,  Sebastian BUNK ,  Felix UNVERDORBEN ,  Frank SCHWOEBEL ,  Dominik MAURER ,  Maike JAWORSKI ,  Claudia WAGNER ,  Florian SCHWOERER ,  Heiko SCHUSTER

IPC: C07K16/30 ,  C07K16/46 ,  C07K16/28

Abstract: The present invention concerns antigen binding proteins directed against PRAME protein-derived antigens. The invention in particular provides antigen binding proteins which are specific for the tumor expressed antigen PRAME, wherein the tumor antigen comprises or consists of SEQ ID NO: 50 and is in a complex with a major histocompatibility complex (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said PRAME peptide. The antigen binding proteins of the invention are for use in the diagnosis, treatment and prevention of PRAME expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising said nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.

公开(公告)号：US20210275655A1

公开(公告)日：2021-09-09

申请号：US17327193

申请日：2021-05-21

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH ,  Claudia WAGNER ,  Julia LEIBOLD ,  Colette SONG

IPC: A61K39/00 ,  A61P35/00 ,  G16B20/20 ,  A61K35/17 ,  C07K14/47 ,  C07K14/725 ,  C07K14/74 ,  C07K16/28 ,  C07K16/30 ,  C12N5/0783 ,  C12Q1/6886 ,  G01N33/574

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20200207849A1

公开(公告)日：2020-07-02

申请号：US16736337

申请日：2020-01-07

Applicant: Immatics Biotechnologies GmbH

Inventor： Felix UNVERDORBEN ,  Sebastian BUNK ,  Martin HOFMANN ,  Dominik MAURER ,  Meike HUTT ,  Claudia WAGNER ,  Leonie ALTEN

IPC: C07K16/28 ,  C07K14/725 ,  C07K16/18 ,  C07K14/78 ,  A61P35/00 ,  C07K14/775 ,  C12N5/0783 ,  C12N15/62

Abstract: The present invention pertains to antigen recognizing constructs against COL6A3 antigens. The invention in particular provides novel engineered T cell receptor (TCR) based molecules which are selective and specific for the tumor expressing antigen COL6A3. The TCR of the invention, and COL6A3 antigen binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of COL6A3 expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.